Global Nivolumab Market, By Type (40 mg/4 mL, 100 mg/10 mL, 240 mg/24 mL), Application (Melanoma, Non-Small Cell Lung Cancer (NSCLC), Malignant Pleural Mesothelioma, Classical Hodgkin Lymphoma (CHL), Squamous Cell Carcinoma of the Head and Neck (SCCHN), Renal Cell Carcinoma (RCC), Others), Demographic (Adult, Pediatric), Dosage (Injection, Solution, Others), Route of Administration (Intravenous, Other), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Industry Trends and Forecast to 2030.
Nivolumab Market Analysis and Size
The global nivolumab market has grown significantly in recent years due to the increased incidence of cancer and the widespread use of immunotherapy treatments. The immune checkpoint inhibitor nivolumab has gained wide acceptance in several cancer indications, including melanoma, lung cancer, renal cell carcinoma, and Hodgkin's lymphoma.
Data Bridge Market Research analyses that the global nivolumab market which was USD 1,456.90 million in 2022, is expected to reach USD 2,736.83 million by 2030, and is expected to undergo a CAGR of 8.20% during the forecast period 2023-2030. This indicates that the market value. “Melanoma” dominates the application segment of the global nivolumab market owing to the growing demand for nivolumab in the treatment of melanoma. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Nivolumab Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (40 mg/4 mL, 100 mg/10 mL, 240 mg/24 mL), Application (Melanoma, Non-Small Cell Lung Cancer (NSCLC), Malignant Pleural Mesothelioma, Classical Hodgkin Lymphoma (CHL), Squamous Cell Carcinoma of the Head and Neck (SCCHN), Renal Cell Carcinoma (RCC), Others), Demographic (Adult, Pediatric), Dosage (Injection, Solution, Others), Route of Administration (Intravenous, Other), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Bristol-Myers Squibb (U.S.), Merck & Co., Inc. (U.S.)Roche Holding AG (Switzerland), AstraZeneca PLC (United Kingdom), Pfizer Inc. (U.S.), Novartis International AG (Switzerland), Johnson & Johnson (U.S.), Amgen Inc. (U.S.), Eli Lilly and Company (U.S.), AbbVie Inc. (U.S.), Sanofi S.A. (France), GlaxoSmithKline PLC (U.K.), Celgene Corporation (U.S.), Boehringer Ingelheim International GmbH (Germany), Takeda Pharmaceutical Company Limited (Japan), Daiichi Sankyo Company, Limited (Japan), Astellas Pharma Inc. (Japan), Bayer AG (Germany), Gilead Sciences, Inc. ((U.S.) and Ipsen (France)
|
|
Market Opportunities
|
|
Market Definition
Nivolumab is a prescription drug that is used for the treatment of metastatic non-small cell lung cancer (NSCLC), classical Hodgkin lymphoma, and renal cell carcinoma. It belongs to the drug class of corticosteroids. It is a PD-1-blocking antibody and is also known as Opdivo.
Global Nivolumab Market Dynamics
Drivers
- Rising Incidence of Cancer
The rising incidence of cancer worldwide is a major driver of the global nivolumab market. As the number of cancer cases continues to increase, the demand for effective immunotherapy drugs such as nivolumab is increasing, leading to the growth of the market.
- Growing Acceptance of Immunotherapy
Immunotherapy has gained significant acceptance as an anticancer therapy in recent years. As an immune checkpoint inhibitor, nivolumab has shown positive clinical results and improved survival in various cancer types. Growing acceptance and trust in immunotherapy by patients and healthcare professionals is leading to market expansion.
- Research and Development Proficiencies
Rising expenditure for research and development proficiencies especially in the developed and developing economies pertaining to the nivolumab will further create lucrative market growth opportunities. Research and development proficiencies being conducted to develop the nivolumab drug are also bolstering the market growth rate.
- Growing Investment in Healthcare Facilities
Surging focus on improving the condition of healthcare facilities and improving the overall healthcare infrastructure is another important factor fostering the growth of the market. The rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities.
Opportunities
- Expansion into New Geographic Markets
One major opportunity for the global nivolumab market is expansion into untapped geographic markets. North America and Europe currently dominate the market, but regions such as Asia Pacific, Latin America, and Africa have significant growth potential. By building partnerships with local healthcare providers, raising awareness of nivolumab, and navigating regulations, pharmaceutical companies can take advantage of the growing demand for cancer immunotherapy in this market.
- Personalized Medicine Approach
The concept of personalized medicine adapted based on a person's unique characteristics, has great potential in the global nivolumab market. A better understanding of the biomarkers and genetic profiles associated with nivolumab response has the potential to develop diagnostics to identify patients most likely to benefit from therapy. This approach can optimize treatment outcomes, minimize unnecessary costs, and improve patient satisfaction.
Restraints/ Challenges
- High Cost of Treatment
One of the main constraints in the global nivolumab market is the high cost of treatment. Immunotherapy, including nivolumab, can be expensive and limit patient access in areas with limited financial resources or underserved health care. The high cost of the treatment may cause issues of affordability, reimbursement, and widespread adoption, which may limit the market growth.
- Side Effects and Safety Concerns
Although nivolumab has shown efficacy in the treatment of various types of cancer, it is not without side effects. Immune-related side effects such as fatigue, rash, diarrhea, and immune-mediated organ toxicity may occur during treatment. Safety concerns and potential side effects may lead to cautious prescribing, patient reluctance, or the need for additional monitoring and management, which may affect the growth potential of the market.
- Regulatory Barriers
Despite the aforementioned favorable regulatory environment, navigating the complex regulatory environment remains a challenge for the nivolumab market. Obtaining formal approvals for expanded indications, managing post-approval requirements, and complying with evolving formal guidelines require significant investments of time, resources, and expertise. The dynamic nature of regulation and the need to meet specific criteria for different types of cancer present ongoing challenges that companies must meet to ensure success in the market.
- Resistance and response variability
Although nivolumab has shown significant efficacy in some patients, there are cases of primary or acquired resistance, and response can vary between individuals. Understanding the mechanisms underlying resistance, identifying predictive biomarkers, and developing strategies to overcome resistance are ongoing challenges in the market. In addition, variability in response to treatment makes accurate prediction and optimization of patient outcomes difficult, further emphasizing the need for individualized medical approaches and combination therapy.
This global nivolumab market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global nivolumab market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In July 2022, Bristol-Myers Squibb Company, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of the fixed-dose combination of nivolumab and relatlimab for the first-line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older
- In March 2022, Nektar Therapeutics and Bristol Myers Squibb Company announced an update following the first analysis of the Phase 3 PIVOT IO-001 study evaluating the doublet therapy of bempegaldesleukin in combination with Opdivo (nivolumab) compared to Opdivo monotherapy as a first-line treatment for previously untreated unresectable or metastatic melanoma
Global Nivolumab Market Scope
The global nivolumab market is segmented on the basis of type, application, demographic, dosage, route of administration, end-users, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- 40 mg/4 mL
- 100 mg/10 mL
- 240 mg/24 mL
Application
- Melanoma
- Non-small Cell Lung Cancer (NSCLC)
- Malignant Pleural Mesothelioma
- Classical Hodgkin Lymphoma (CHL)
- Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Renal Cell Carcinoma (RCC)
- Others
Demographic
- Adult
- Pediatric
Dosage
- Injection
- Solution
- Others
Route of Administration
- Intravenous
- Others
End-Users
- Hospitals
- Clinics
- Others
Dosage
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Global Nivolumab Market Regional Analysis/Insights
The global nivolumab market is analysed and market size insights and trends are provided by country, type, application, demographic, dosage, route of administration, end-users, and distribution channel as referenced above.
The countries covered in the global nivolumab market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the global nivolumab market due to the presence of major key players, a well-developed healthcare sector, and high disposable income in this region.
Asia-Pacific is expected to grow during the forecast period 2023 to 2030 due to the increasing research and development activities, rise in the prevalence of non-small cell lung cancer (NSCLC), and growing government support.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The global nivolumab market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global nivolumab market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global nivolumab market. The data is available for historic period 2023-2030.
Competitive Landscape and Global Nivolumab Market Share Analysis
The global nivolumab market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the global nivolumab market.
Some of the major players operating in the global nivolumab market are:
- Bristol-Myers Squibb (U.S.)
- Merck & Co., Inc. (U.S.)
- Roche Holding AG (Switzerland)
- AstraZeneca PLC (United Kingdom)
- Pfizer Inc. (U.S.)
- Novartis International AG (Switzerland)
- Johnson & Johnson (U.S.)
- Amgen Inc. (U.S.)
- Eli Lilly and Company (U.S.)
- AbbVie Inc. (U.S.)
- Sanofi S.A. (France)
- GlaxoSmithKline PLC (U.K.)
- Celgene Corporation (U.S.)
- Boehringer Ingelheim International GmbH (Germany)
- Takeda Pharmaceutical Company Limited (Japan)
- Daiichi Sankyo Company, Limited (Japan)
- Astellas Pharma Inc. (Japan)
- Bayer AG (Germany)
- Gilead Sciences, Inc. ((U.S.)
- Ipsen (France)
SKU-